Preimplantation Genetic Testing Companies

The preimplantation genetic testing market is projected to grow from USD 1,135.0 million in 2025 to USD 1,935.2 million in 2030, at a CAGR of 10.5% during the forecast period. The market is driven by the rising prevalence of genetic and chromosomal disorders, increasing infertility rates, and growing adoption of assisted reproductive technologies (ART). The increasing use of advanced genomic tools, such as next-generation sequencing (NGS) and array-based technologies, is further enhancing the accuracy and reliability of embryo screening. Additionally, increasing awareness of genetic health, coupled with the demand for improved IVF success rates, is propelling the adoption of preimplantation genetic testing in fertility clinics worldwide.

The preimplantation genetic testing market is consolidated. The prominent players operating in this market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), Revvity (US), CooperCompanies (US), Abbott (US), Takara Bio Inc. (Japan), QIAGEN (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies pIc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), and Bangkok Genomics Innovation (Thailand). These market players have implemented various strategies, including product launches, acquisitions, collaborations, and expansions, to strengthen their market positions in preimplantation genetic testing.In October 2025, Illumina launched its new 5-base sequencing solution, a next-generation platform that enables the simultaneous detection of genomic variants and DNA methylation patterns from a single sample. This platform is designed to enhance the analytic capabilities of embryo screening and diagnostic workflows for IVF and reproductive health labs, improving clinical outcomes and data accuracy within preimplantation genetic testing.

To know about the assumptions considered for the study download the pdf brochure

In October 2025, Illumina announced a collaboration with GeneDx to pilot its Constellation Mapped Read Technology, which uncovers hard-to-detect genomic variants in embryo samples for preimplantation genetic testing applications. This partnership leverages Illumina’s platform innovations and GeneDx’s expertise in clinical genetics to improve the detection of rare inherited disorders, further enhancing the precision and scope of embryo screening for IVF clinics.

Illumina, Inc. (US)

Illumina is a leading player in the preimplantation genetic testing market, recognized for its advanced sequencing platforms, consumables, and data analysis solutions. The company’s next-generation sequencing (NGS) technologies enable highly accurate detection of chromosomal abnormalities, single-gene mutations, and structural variants in embryos. Illumina continues to enhance its portfolio through technological innovations, such as the NovaSeq and NextSeq platforms, along with specialized workflows like VeriSeq, which are designed for reproductive health applications. Strategic collaborations and R&D investments strengthen its position in clinical genomics, enabling faster and more comprehensive embryo screening. By integrating automation and informatics, Illumina enables fertility clinics and genetic testing laboratories to enhance diagnostic precision, streamline IVF workflows, and improve patient outcomes in reproductive medicine.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a key contributor to the preimplantation genetic testing market, offering a comprehensive suite of instruments, reagents, and software designed for reproductive genetics. The company’s Ion Torrent sequencing technology and Ion ReproSeq PGT kits offer reliable, high-throughput genomic analysis of embryos, enabling the accurate detection of aneuploidies and monogenic disorders. The company focuses on integrating NGS workflows with advanced bioinformatics to deliver end-to-end solutions for IVF laboratories. Continuous product development, combined with strategic partnerships and global reach, allows Thermo Fisher to expand its presence in the reproductive health domain. With a strong emphasis on workflow automation, data accuracy, and scalability, the company plays a pivotal role in advancing genetic screening and improving IVF success rates worldwide.

Agilent Technologies, Inc. (US)

Agilent Technologies holds a notable position in the preimplantation genetic testing market, leveraging its strengths in genomics, microarrays, and bioinformatics. The company’s high-resolution array comparative genomic hybridization (aCGH) and next-generation sequencing tools support comprehensive chromosomal and genomic analysis in embryo testing. Agilent’s SurePrint microarrays and SureFISH platforms are widely used for high-confidence genomic profiling and structural variant detection. Through continuous innovation, strategic collaborations, and software integration, Agilent enhances workflow efficiency and diagnostic reliability for reproductive genetics applications. Its global distribution network and commitment to quality empower fertility clinics and genetic laboratories to achieve reproducible, precise, and scalable results, solidifying Agilent’s position as a trusted technology partner in the preimplantation genetic testing market.

Market Ranking

The preimplantation genetic testing market is characterized by significant competition, with the leading players capturing approximately 49–52% of the total market share. Illumina, Inc. holds a prominent position, driven by its comprehensive portfolio encompassing sequencing platforms, reagents, and advanced bioinformatics solutions tailored for reproductive genetics. The company’s focus on next-generation sequencing–based testing and automation enables high-throughput, accurate, and cost-effective embryo analysis. Thermo Fisher Scientific Inc. and Agilent Technologies, Inc. also command substantial market shares through continuous investment in R&D aimed at improving analytical precision, workflow efficiency, and clinical applicability in embryo screening and genetic diagnosis.

The emerging growth potential in the Asia Pacific and Latin American regions offers opportunities for companies to expand their presence amid rising infertility rates, delayed pregnancies, and growing adoption of assisted reproductive technologies (ART). Increasing awareness of the benefits of genetic testing, supportive healthcare policies, and improved IVF infrastructure are driving regional demand. Regional and emerging players account for the remaining 48–51% of the market share, leading to notable consolidation within the sector.

The prominent players in the preimplantation genetic testing market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and CooperCompanies (US). These companies have adopted organic and inorganic strategies, including product launches, partnerships, and acquisitions, to strengthen their market presence and maintain their leading positions in the market.

Related Reports:

Preimplantation Genetic Testing Market by Product & Service (Reagents, Consumables, Instruments, Software), Technology (NGS, PCR, SNP, CGH), Procedure (Screening, Diagnosis), Application (Aneuploidy, HLA Typing), Type of cycle - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com